Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Rhea-AI Summary

Exicure, Inc. (Nasdaq: XCUR) received a notice of non-compliance from Nasdaq due to the delayed filing of its Quarterly Report on Form 10-Q. The company has 60 days to submit a plan to regain compliance and can be granted up to 180 days to do so. Exicure is working diligently to complete the form and intends to file it as soon as possible.

Positive

• None.

Negative

• Exicure received a notice of non-compliance from Nasdaq due to the delayed filing of its Quarterly Report on Form 10-Q, which may indicate internal operational issues or challenges with financial reporting processes.

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 22, 2023 notifying the Company that, as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).

Under Nasdaq’s listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 10-Q due date, or until May 20, 2024, to regain compliance.

The Company is working diligently to complete its Form 10-Q and intends to file the Form 10-Q as soon as practicable to regain compliance with the Rule.

About Exicure

Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company’s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “advance,” “believes,” “target,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 27, 2023, as updated by the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231128399020/en/

Lavinia Jurkiewicz

847-673-2910

Lavinia@exicuretx.com

Source: Exicure, Inc.

FAQ

What is the ticker symbol for Exicure, Inc.?

The ticker symbol for Exicure, Inc. is XCUR.

Why did Exicure receive a notice of non-compliance from Nasdaq?

Exicure received a notice of non-compliance from Nasdaq due to the delayed filing of its Quarterly Report on Form 10-Q.

How long does Exicure have to submit a plan to regain compliance?

Exicure has 60 calendar days to submit a plan to regain compliance with Nasdaq.

How long can Exicure be granted to regain compliance after submitting a plan?

If the plan is accepted by Nasdaq, Exicure can be granted up to 180 calendar days to regain compliance, until May 20, 2024.

What is Exicure doing to regain compliance with Nasdaq?

Exicure is working diligently to complete its Form 10-Q and intends to file the form as soon as practicable to regain compliance with Nasdaq Listing Rule 5250(c)(1).